Tarsus Pharmaceuticals (TARS) Misses Q4 Earnings Expectations

Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly earnings results on February 23, 2026 that fell short of analyst expectations.

The Healthcare company reported earnings per share of $-0.20, missing the consensus estimate of $-0.07 by $0.13 per share. Revenue came in at $151.7M, beating the estimate of $144.7M.

Tarsus Pharmaceuticals's stock moved following the earnings release. The stock currently trades at $78.32 with a market capitalization of $3.5B.